Gautam S.D. Balasubramania Pandian

Gautam S.D. Balasubramania Pandian

Auto-generated profile, based on publicly available information

Gautam S.D. Balasubramania Pandian

S.A. Localio Laboratory, Department of Surgery, New York University School of Medicine, New York, NY 10016

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DDDonnele Daley
Donnele Daley
VMVishnu R. Mani
Vishnu R. Mani
NMNavyatha Mohan
Navyatha Mohan
NANeha Akkad
Neha Akkad
GPGautam S.D. Balasubramania Pandian
Gautam S.D. Balasubramania Pandian
GMGeorge Miller
George Miller
The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDA) is characterized by immune tolerance, which enables disease to progress unabated by adaptive immunity. However, the drivers of this tolerogenic program are incompletely defined. In this study, we found that NLRP3 promotes expansion of immune-suppressive macrophages in PDA. NLRP3 signaling in macrophages drives the differentiation of CD4+ T cells into tumor-promoting T helper type 2 cell (Th2 cell), Th17 cell, and regulatory T cell populations while suppressing Th1 cell polarization and cytotoxic CD8+ T cell activation. The suppressive effects of NLRP3 signaling were IL-10 dependent. Pharmacological inhibition or deletion of NLRP3, ASC (apoptosis-associated speck-like protein containing a CARD complex), or caspase-1 protected against PDA and was associated with immunogenic reprogramming of innate and adaptive immunity within the TME. Similarly, transfer of PDA-entrained macrophages or T cells from NLRP3−/− hosts was protective. These data suggest that targeting NLRP3 holds the promise for the immunotherapy of PDA.